Support for developing personalized genomic medicine

Abstract

This article discusses the benefits of personalized genomic medicine, some of the challenges of adoption into the clinic, and provides examples of UK and European projects that are developing the practice of personalized genomic medicine. It highlights the work of the UK Pharmacogenetics and Stratified Medicine Network in providing information, developing multidisciplinary collaborations, and organizing events, to support the advancement of personalized genomic medicine.

Keywords

Pharmacogenetics / personalized medicine / genomics / drug development / safety

References

[1] Parkes M.Personalised medicine and genetic prediction--are we there yet?.Clin Med (Lond)2013;13:s62-4

[2] Singh S.Stratified medicine: maximizing clinical benefit by biomarker-driven health care..Nestle Nutr Inst Workshop2016;84:91-102

[3] Hood L.Predictive, personalized, preventive, participatory (P4) cancer medicine..Nat Rev Clin Oncol2011;8:184-7

[4] Hamann U.Hereditary breast cancer: high-risk genes, genetic testing and clinical implications..Clin Lab2000;46:447-61

[5] Bell J. Life sciences industrial strategy. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/650447/LifeSciencesIndustrialStrategy_acc2.pdf. [Last accessed on 1 Nov 2018]

[6] Brittain HK,Thomas E.The rise of the genome and personalised medicine..Clin Med (Lond)2017;17:545-51

[7] Patel JN,Dunnenberger HM.Value of supportive care pharmacogenomics in oncology practice..Oncologist2018;23:956-64 PMCID:PMC6156181

[8] FDA. Table of pharmacogenomic biomarkers in drug labeling. Available from: https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm. [Last accessed on 1 Nov 2018]

[9] Zhao X,Carayannopoulos LN.Biomarkers in pharmaceutical research..Clin Chem2015;61:1343-53

[10] Genomics England. 100,000 genome project. Available from: https://www.genomicsengland.co.uk. [Last accessed on 1 Nov 2018]

[11] UK Pharmacogenetics and Stratified Medicine Network. NHS England’s policy and infrastructure plans - Ellen Graham. Available from: http://www.uk-pgx-stratmed.co.uk/index.php/nhs-england-s-policy-and-infrastructure-plans-ellen-graham.html. [Last accessed on 1 Nov 2018]

[12] U-PGx. U-PGx PREPARE study. Available from: http://upgx.eu/study. [Last accessed on 1 Nov 2018]

[13] Personalized Medicine Coalition. Personalized medicine at FDA: 2017 progress report. Available from: http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/PM_at_FDA_2017_Progress_Report.pdf. [Last accessed on 1 Nov 2018]

[14] Spear BB,Huff J.Clinical application of pharmacogenetics..Trends Mol Med2001;7:201-4

[15] Chaponda M.Hypersensitivity reactions to HIV therapy..Br J Clin Pharmacol2011;71:659-71 PMCID:PMC3093072

[16] UK Pharmacogenetics and Stratified Medicine Network. Pharmacogenomics of serious adverse drug reactions - Munir Pirmohamed. Available from: http://www.uk-pgx-stratmed.co.uk/index.php/pharmacogenomics-of-serious-adverse-drug-reactions-munir-pirmohamed.html. [Last accessed on 1 Nov 2018]

[17] Osanlou O,Daly AK.Pharmacogenetics of adverse drug reactions..Adv Pharmacol2018;83:155-90

[18] Doostparast Torshizi A.Next-generation sequencing in drug development: target identification and genetically stratified clinical trials..Drug Discov Today2018;23:1776-83

[19] Paul SM,Dunwiddie CT,Munos BH.How to improve R&D productivity: the pharmaceutical industry’s grand challenge..Nat Rev Drug Discov2010;9:203-14

[20] Simon R.Critical review of umbrella, basket, and platform designs for oncology clinical trials..Clin Pharmacol Ther2017;102:934-41

[21] Roberts J.Genetics in the 21st Century: implications for patients, consumers and citizens. Version 2..F1000Res2017;6:2020 PMCID:PMC5721930.2

[22] UK Pharmacogenetics and Stratified Medicine Network. Available from: http://www.uk-pgx-stratmed.co.uk. [Last accessed on 1 Nov 2018]